Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a ...

Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...

an experimental Chinese drug showed it could one day become an important therapy for lung cancer patients. But that doesn’t necessarily threaten the market dominance of Keytruda, a top Merck ...

(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

We recently compiled a list of the 7 Best Stocks for Beginners with Little Money According ... The FDA’s late March approval of pulmonary arterial hypertension drug sotatercept, also drove share gains ...

We recently compiled a list of the 10 Best Defensive Stocks According to Reddit ... The FDA’s late March approval of pulmonary arterial hypertension drug sotatercept, also drove share gains. We retain ...